Last month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…

Huda Zoghbi Biography and Net Worth

Director of Regeneron Pharmaceuticals

Huda Y. Zoghbi, M.D., joined the Board in September 2016. Dr. Zoghbi is a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and an investigator of the Howard Hughes Medical Institute. Dr. Zoghbi has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science. She has been awarded numerous recognitions for her work including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science.

Dr. Zoghbi earned her B.Sc. from the American University of Beirut, received her M.D. from Meharry Medical College in Nashville, Tennessee, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.

What is Huda Y. Zoghbi's net worth?: The estimated net worth of Huda Y. Zoghbi is at least $920,286.00 as of October 13th, 2023. Dr. Zoghbi owns 1,247 shares of Regeneron Pharmaceuticals stock worth more than $920,286 as of November 23rd. This net worth estimate does not reflect any other assets that Dr. Zoghbi may own. Learn More about Huda Y. Zoghbi's net worth.
How do I contact Huda Y. Zoghbi?: The corporate mailing address for Dr. Zoghbi and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Huda Y. Zoghbi's contact information.
Has Huda Y. Zoghbi been buying or selling shares of Regeneron Pharmaceuticals?: Huda Y. Zoghbi has not been actively trading shares of Regeneron Pharmaceuticals over the course of the past ninety days. Most recently, Huda Y. Zoghbi sold 1,000 shares of the business's stock in a transaction on Friday, October 13th. The shares were sold at an average price of $850.00, for a transaction totalling $850,000.00. Following the completion of the sale, the director now directly owns 1,247 shares of the company's stock, valued at $1,059,950. Learn More on Huda Y. Zoghbi's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 28 times. They sold a total of 108,095 shares worth more than $105,638,222.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Huda Y. Zoghbi Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/13/2023	Sell	1,000	$850.00	$850,000.00	1,247
6/11/2020	Sell	3,412	$588.39	$2,007,586.68

Huda Y. Zoghbi Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $738.00

$737.63

$751.40

50 Day Range

MA: $945.07

$738.00

$1,153.08

2 Week Range

Now: $738.00

$735.95

$1,211.20

Volume

1,029,423 shs

Average Volume

539,322 shs

Market Capitalization

$81.10 billion

P/E Ratio

18.26

Dividend Yield

N/A

Beta

0.15

I hate to say I told you so

From WealthPress | Ad

Follow this link right away.